Lubilax 8 mcg (Capsule)
Unit Price: ৳ 15.05 (3 x 10: ৳ 451.50)
Strip Price: ৳ 150.50
Medicine Details
| Category | Details |
|---|---|
| Generic | Lubiprostone |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Irritable Bowel Syndrome with Constipation (IBS-C)
- Chronic Idiopathic Constipation (CIC) in adults
- Opioid-Induced Constipation (OIC) in adult patients with chronic, non-cancer pain
Pharmacology
- locally-acting chloride-channel activator
- increases intestinal secretion
- increases intestinal motility
- activates ClC-2 chloride channels
- causes efflux of chloride ions into the lumen
- leads to efflux of sodium ions through a paracellular pathway
- stimulates the recovery of muscosal barrier function
- increases motility in the intestine
- restores tight junction protein complexes in the intestine
Dosage & Administration
- Recommended dose is 8 mcg twice daily orally with food and water for Irritable Bowel Syndrome with Constipation
- Dosage adjustment is not required for patients with moderately impaired hepatic function
- Recommended dose is 24 mcg twice daily orally with food and water for Chronic Idiopathic Constipation and Opioid-induced Constipation
- For patients with moderately impaired hepatic function, the recommended starting dose is 16 mcg twice daily
- For patients with severely impaired hepatic function, the recommended starting dose is 8 mcg twice daily
Interaction
- Dose-dependent decrease in the efficacy of Lubilax in patients using diphenylheptane opioids
Contraindications
- Contraindicated in patients with known or suspected mechanical gastrointestinal obstruction
Side Effects
- Diarrhea
- full or bloated feeling or pressure in the stomach
- nausea
- stomach pain
- swelling of abdominal or stomach area
- Dyspnea
Pregnancy & Lactation
- Pregnancy category C
- It is not known whether lubiprostone is excreted in human milk
- Human milk-fed infants should be monitored for diarrhea
- Caution should be exercised when Lubiprostone is administered to a nursing woman
Precautions & Warnings
- Patients may experience nausea
- Concomitant administration of food with Lubilax may reduce symptoms of nausea
- Lubistone should not be prescribed to patients that have severe diarrhea
- In patients with symptoms suggestive of mechanical gastrointestinal obstruction, perform a thorough evaluation to confirm the absence of an obstruction prior to initiating therapy with Lubilax
Overdose Effects
- Adverse reactions due to overdose may include: nausea, diarrhea, vomiting, dizziness, headache, abdominal pain, flushing/hot flash, retching, dyspnea, pallor, stomach discomfort, anorexia, asthenia, chest discomfort, dry mouth, hyperhidrosis, syncope
Therapeutic Class
- Other laxative preparations
Storage Conditions
- Store between 15-30 degrees C